Exelixis
EXEL
#1587
Rank
C$19.45 B
Marketcap
C$77.40
Share price
2.50%
Change (1 day)
30.33%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): C$4.31

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$4.44. In 2025 the company made an earnings per share (EPS) of C$4.10.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$4.315.22%
2025C$4.10
2023C$0.9314.61%
2022C$0.81-22.97%
2021C$1.05100%
2020C$0.52-65.09%
2019C$1.50-53.91%
2018C$3.26333.96%
2017C$0.75-260.61%
2016C-$0.47-58.75%
2015C-$1.13-42.45%
2014C-$1.975.3%
2013C-$1.87

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$12.39 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.86-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$20.54 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$3.63-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$5.05 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$5.05 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$5.51 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$5.21-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.19-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA